Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Disitamab vedotin - Yantai Rongchang Pharmaceutical

Next Previous
X
Search
Drug Profile

Disitamab vedotin - Yantai Rongchang Pharmaceutical

Alternative Names: Aidixi; RC 48; RC 48-ADC; Recombinant Humanized anti-HER2 Monoclonal Antibody-MMAE Conjugate - Yantai Rongchang Pharmaceutical

Latest Information Update: 02 Sep 2024

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Yantai Rongchang Biological Engineering
  • Developer RemeGen; Seagen
  • Class Antineoplastics; Auristatins; Drug conjugates; Immunotoxins; Monoclonal antibodies
  • Mechanism of Action Tubulin polymerisation inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Gastric cancer
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Gastric cancer
  • Registered Urogenital cancer
  • Phase III HER2 positive breast cancer
  • Phase II Biliary cancer; Bladder cancer; Breast cancer; Cervical cancer; Gynaecological cancer; Malignant melanoma; Solid tumours
  • Phase I/II Non-small cell lung cancer
  • Phase I Prostate cancer

Most Recent Events

  • 23 Aug 2024 RemeGen withdraws a phase II trial in Breast cancer (Late-stage disease, Combination therapy, Metastatic disease, Second-line therapy or greater, Inoperable/Unresectable) in China (IV) due to company's strategic adjustment (NCT06105008)
  • 17 Jul 2024 3863938 - no updates/data already covered
  • 16 Jun 2024 Phase-I/II clinical trials in Bladder cancer in China (IV) (NCT06378242, RC48-C029)

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top